ClinicalTrials.gg
TerminatedNCT05828589Updated Jul 14, 2026

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

A Phase 1 interventional study of BGB-21447 in Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma and Relapsed Chronic Lymphocytic Leukemia, sponsored by BeOne Medicines. Terminated at 28 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by BeOne Medicines · Phase 1, Interventional, and Treatment

Why this study was terminated
This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Enrollment
96th of 183
51 · median 58
Started
2023
with 22 others
Phase 1
79 of 196
33 open now
Registered
136th of 196
by date
Lead sponsor
4 of 196
BeOne Medicines

Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 96th largest by enrollment of the 183 interventional ones that give a count, is one of 23 that started in 2023, is one of 79 in phase 1, and was the 136th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

This study is testing the safety and tolerability of BGB-21447 monotherapy in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study aims to determine the maximum tolerated dose (MTD), maximum administered dose (MAD), recommended Phase 2 dose (RP2D), and pharmacokinetic profile of the drug. Additionally, preliminary antitumor activity will be characterized. The study is divided into 2 main parts: Part 1 "Monotherapy Dose Finding" and Part 2 "Monotherapy Dose Optimization."

Read the detailed description

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

03

Conditions studied

  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Chronic Lymphocytic Leukemia
  • Refractory Chronic Lymphocytic Leukemia
  • Relapsed Follicular Lymphoma
  • Relapsed Marginal Zone Lymphoma
  • Relapse Diffuse Large B Cell Lymphoma
  • Relapsed Small Lymphocytic Lymphoma
  • Refractory Follicular Lymphoma
  • Refractory Marginal Zone Lymphoma
  • Refractory Small Lymphocytic Lymphoma
  • Richter Transformation
  • Refractory Diffuse Large B-cell Lymphoma
  • Transformed Non-Hodgkin Lymphoma

Keywords

  • Relapsed Non-Hodgkin Lymphoma
  • refractory non-Hodgkin lymphoma
  • Relapsed Chronic Lymphocytic Leukemia
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • NHL
  • FL
  • MZL
  • Refractory Chronic Lymphocytic Leukemia
  • RCLL
  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma
  • Relapsed Marginal Zone Lymphoma
  • Refractory Marginal Zone Lymphoma
  • RFL
  • RMZL
  • Relapsed Small Lymphocytic Lymphoma
  • Refractory Small Lymphocytic Lymphoma
  • RSLL
  • Richter's transformation
  • RT
  • RR DLBCL
  • Bcl-2
  • Bcl-2i
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis (per World Health Organization [WHO] guidelines, unless otherwise noted) of one of the following:

    Cohort A1 and Cohort A2:

    1. R/R DLBCL (for Cohort A1 and Cohort A2.1)

      • High-grade B-cell lymphomas with translocations of MYC and Bcl-2 and/or Bcl-6 are not allowed in Cohort A1 but may be allowed in Cohort A2.1
    2. R/R FL (for Cohort A1 and Cohort A2.2)
    3. R/R MZL (for Cohort A1 and Cohort A2.2)
    4. Transformed B-cell NHL (for Cohort A1 only)
    5. Richter's transformation to DLBCL (for Cohort A1 only)
  2. by computed tomography/magnetic resonance imaging.

Exclusion criteria

Exclusion Criteria:

  1. Prior (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer or lentigo maligna melanoma that has been curatively resected
  2. Known central nervous system involvement by lymphoma/leukemia
  3. Prior stem cell transplant \< 3 months before the first dose of study drug. Or prior chimeric antigen receptor T-cell (CAR-T) therapy \< 3 months before the first dose of study drug
  4. Prior allogeneic stem cell transplant.
  5. Major surgery \< 4 weeks before the first dose of study treatment

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Part 1 (Cohort A1): Dose escalation in patients with B-cell non-Hodgkin lymphoma (NHL)

    Participants with R/R B-cell NHL (including diffuse large B-cell lymphoma \[DLBCL\], follicular lymphoma \[FL\], marginal zone lymphoma \[MZL\], transformed B-cell NHL (B-NHL), and Richter's transformation to DLBCL) will receive BGB-21447 once a day.

    Drug: BGB-21447

  • Experimental
    Part 1 (Cohort B): Dose escalation in R/R CLL/SLL participants with low tumor burden

    Participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) will receive BGB-21447 once a day.

    Drug: BGB-21447

  • Experimental
    Part 2 (Cohort A2.1): BGB-21447 Monotherapy Dose Optimization in R/R DLBCL

    Participants will receive BGB-21447 with two dose levels from Cohort A1 for further evaluation of safety and efficacy.

    Drug: BGB-21447

  • Experimental
    Part 2 (Cohort A2.2): BGB-21447 Monotherapy Dose Optimization in R/R FL or R/R MZL

    Participants will receive BGB-21447 with two dose levels from Cohort A1 for further evaluation of safety and efficacy.

    Drug: BGB-21447

Interventions

  • DrugBGB-21447

    BGB-21447 will be administered orally

06

What researchers measure

Primary outcomes

  1. Part 1: Number of participants with dose limiting toxicities (DLTs)

    Number of participants with dose limiting toxicities, as defined in the study protocol.

    Time frame: Up to approximately 1 month

  2. Number of participants with adverse events (AEs)

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) assessed and graded based upon the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0).

    Time frame: From the first dose of study drug to 30 days after the last dose or initiation of new anticancer therapy, whichever occurs first; up to approximately 12 months

  3. Number of participants with Tumor Lysis Syndrome (TLS)

    TLS will be determined via laboratory values and assessed by the investigator. In laboratory tumor lysis syndrome, 2 or more metabolic abnormalities must be present during the 24-hour period within 3 days before the start of study drug treatment or up to 7 days afterward. Clinical tumor lysis syndrome requires the presence of laboratory tumor lysis syndrome plus an increased creatinine level, seizures, cardiac dysrhythmia, or death.

    Time frame: From the first dose of study drug to 30 days after the last dose or initiation of new anticancer therapy, whichever occurs first; up to approximately 12 months

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax) After a Single Dose of BGB-21447

    Time frame: Up to approximately 8 weeks

  2. Area under the curve from time 0 to the last sampling time point within the dose interval (AUC0-t) After a Single Dose of BGB-21447

    Time frame: Up to approximately 8 weeks

  3. Area under the curve from time 0 extrapolated to infinity time (AUCinf) After a Single Dose of BGB-21447

    Time frame: Up to approximately 8 weeks

  4. Time to reach maximum observed plasma concentration (Tmax) After a Single Dose of BGB-21447

    Time frame: Up to approximately 8 weeks

  5. Apparent terminal elimination half-life (t1/2) After a Single Dose of BGB-21447

    Time frame: Up to approximately 8 weeks

  6. Apparent oral clearance (CL/F) After a Single Dose of BGB-21447

    Time frame: Up to approximately 8 weeks

  7. Apparent volume of distribution (Vz/F) After a Single Dose of BGB-21447

    Time frame: Up to approximately 8 weeks

  8. Steady state maximum observed plasma concentration (Cmax,ss) of BGB-21447

    Time frame: Up to approximately 8 weeks

  9. Steady state pre-dose trough concentration (Ctrough,ss) of BGB-21447

    Time frame: Up to approximately 8 weeks

  10. Steady state area under the curve from time 0 to the quantifiable concentration (AUClast,ss) of BGB-21447

    Time frame: Up to approximately 8 weeks

  11. Steady state time to reach maximum observed plasma concentration (Tmax,ss) of BGB-21447

    Time frame: Up to approximately 8 weeks

  12. Overall response rate (ORR)

    Defined as the percentage of patients who achieve partial response or better for diffuse large B-cell lymphoma, marginal zone lymphoma, follicular lymphoma, transformed B-NHL, and Richter's transformation to DLBCL as per the Lugano Classification for non-Hodgkin lymphoma.

    Time frame: Up to approximately 24 months

  13. Duration of Response (DOR)

    Defined as the time from the first response documentation to the date that progression is documented after treatment initiation or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 24 months

  14. Time to response (TTR)

    Defined as the time from treatment initiation to the first documentation of response.

    Time frame: Up to approximately 24 months

  15. Part 2: Progression-free survival (PFS)

    Defined as the time from treatment initiation to the first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 24 months

07

Study locations

28 sites
  • Sibley Memorial Hospital Johns Hopkins Medicine
    Washington D.C., District of Columbia 20016, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242-1009, United States
  • Mission Cancer and Blood
    Waukee, Iowa 50263, United States
  • Sidney Kimmel Comprehensive Cancer At Johns Hopkins
    Baltimore, Maryland 21287, United States
  • Nyu Langone Health Perlmutter Cancer Center At Nyu Langone Hospital Long Island
    Mineola, New York 11501, United States
  • Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health
    New York, New York 10016-2708, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105-2108, United States
  • Blacktown Cancer and Haematology Centre
    Blacktown, New South Wales NSW 2148, Australia
  • Pindara Private Hospital
    Benowa, Queensland QLD 4217, Australia
  • Mater Cancer Care Centre
    South Brisbane, Queensland QLD 4101, Australia
  • Monash Health
    Clayton, Victoria VIC 3168, Australia
  • Linear Clinical Research
    Nedlands, Western Australia WA 6009, Australia
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100000, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Yichang Central Peoples Hospitaljiangnan Branch
    Yichang, Hubei 443001, China
  • The First Peoples Hospital of Changzhou
    Changzhou, Jiangsu 213000, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • The First Affiliated Hospital of Nanchang University Branch Xianghu
    Nanchang, Jiangxi 332000, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • Shandong Provincial Hospital
    Jinan, Shandong 250021, China
  • Linyi Peoples Hospital
    Linyi, Shandong 276000, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin Municipality 300020, China
  • Auckland City Hospital
    Auckland, 1023, New Zealand
08

References and documents

Individual participant data

Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jun 2026, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
Apr 25, 2023
StartActual
Jun 20, 2023
Primary completionActual
Jun 8, 2026
CompletionActual
Jun 8, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05828589
Lead sponsor
BeOne Medicines
Responsible party
Sponsor
First posted
Apr 25, 2023
Start date
Jun 20, 2023
Primary completion
Jun 8, 2026
Completion
Jun 8, 2026
Last update
Jul 14, 2026

Study contacts

Study Director
study director · BeOne Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion